PHA’s PH Care Centers (PHCC) Program Accredits Five New Centers

2020-12-21T14:31:18-05:00April 4th, 2019|

The Pulmonary Hypertension Association’s (PHA’s) PH Care Centers (PHCC) Program recently accredited five new centers in support of its commitment to promoting quality care practices through PH center accreditation. Interest in PHA’s continuous quality improvement initiative remains high as PH programs seek accreditation as Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP).

Novel Clinical Trial Designs Featured in Advances-Published Paper

2020-12-21T14:30:35-05:00March 28th, 2019|

The Pulmonary Hypertension Association (PHA) just launched its new Clinical Trial Finder that allows individuals to search for research in pulmonary hypertension (PH), so it seems fitting to highlight a paper published in the most recent edition of Advances in Pulmonary Hypertension, “Basic Science and Clinical Trials: Accelerating the Future.” Authors Stephen J. Halliday,

Advances in Pulmonary Hypertension Looks at Different Approaches to Treat Pediatric PH

2020-12-21T14:29:52-05:00February 7th, 2019|

Although the World Symposium on Pulmonary Hypertension (WSPH) has led pulmonary hypertension (PH) to be considered in five classifications, or groups, pediatric PH is more nuanced and there is increasing recognition of unique genotypic and phenotypic subsets of the disease. This necessitates individualized and precision approaches to treatments for children with PH that will

PHA’s Online Advances in Pulmonary Hypertension Examines Barriers in New PH Therapies

2020-12-21T14:28:56-05:00January 31st, 2019|

The latest issue of Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association (PHA) — a free quarterly publication directed by an editorial board of renowned pulmonary hypertension (PH) experts — includes an article by Brian Graham, M.D., Peter Fernandes, M. Pharm., and Sue Gu, M.D., that explores the barriers and solutions to

PHA Publishes New Online CME Courses for Health Care Professionals

2020-12-21T14:29:00-05:00January 10th, 2019|

The Pulmonary Hypertension Association (PHA) recently published three new courses on PHA Online University, a program of PHA’s multi-sponsored Medical Education Fund and the go-to web platform for health care professionals to acquire relevant and reliable information about pulmonary hypertension (PH). The courses are part of the “Pulmonary Hypertension: The Basics” curriculum series to educate

PHA Registry Expands Access to PH Data Service

2020-12-21T15:30:38-05:00December 6th, 2018|

A new Data Analysis Service launched this week by the Pulmonary Hypertension Association (PHA) enables researchers and organizations not involved in PHA’s Pulmonary Hypertension Association Registry (PHAR) to use data from the multi-center patient registry. PHAR is part of an innovative and critical PHA initiative to improve care for persons with pulmonary hypertension (PH),

PHPN Mentor Program Provides Valuable Lessons to Health Care Professionals

2020-12-21T15:27:11-05:00September 21st, 2018|

The diagnosis of pulmonary hypertension (PH) is overwhelming in patients’ and caregivers’ lives. It also can prove challenging to health care professionals new to the field. Before health care professionals were experts, they were studying and training underneath their mentors to learn quality patient care and implement best practices. The Pulmonary Hypertension Association’s (PHA) PH

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2020-12-21T15:25:56-05:00August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving

FDA Approves Generic Version of Adcirca®; Additional Approvals May Come Soon

2020-12-21T15:26:03-05:00August 17th, 2018|

The Pulmonary Hypertension Association (PHA) recently learned that the Food and Drug Administration (FDA) has approved a generic version of tadalafil, the pulmonary arterial hypertension (PAH)-targeted therapy sold as Adcirca®. Availability of the generic therapy for patients remains to-be-determined. PHA also has been advised that generic versions of other PAH-targeted therapies may become available soon.